Interleukin-1, Tumour Necrosis Factor and Treatment of the Septic Shock Syndrome
Treating the septic shock syndrome with antibodies that block only endotoxin has its limitations. Other targets for treating septic shock include neutralizing antibodies to the complement fragment C5a, platelet activating factor antagonists and blockade of endothelial cell leukocyte adhesion molecul...
Saved in:
Main Author: | Charles A Dinarello |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
1992-01-01
|
Series: | Canadian Journal of Infectious Diseases |
Online Access: | http://dx.doi.org/10.1155/1992/652727 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Exercise Training on Interleukin-6, Tumour Necrosis Factor Alpha and Functional Capacity in Heart Failure
by: Neil A. Smart, et al.
Published: (2011-01-01) -
Evaluation of Tumour Necrosis Factor-Alpha and Interleukin-1beta in an Experimental Pyelonephritis Model Induced with Planktonic and Biofilms Cells of Pseudomonas aeruginosa
by: Rahul Mittal, et al.
Published: (2009-01-01) -
Tumor necrosis factor, interleukin-1 and interleukin-8 mediate the nociceptive activity of the supernatant of LPS-stimulated macrophages
by: S. M. Thomazzi, et al.
Published: (1997-01-01) -
Septic Shock and Spontaneous Gangrenous Gas Necrosis of the Spleen Secondary to Clostridium perfringens: The Importance of Source Control
by: Morgan Oskutis, et al.
Published: (2021-01-01) -
Kawasaki Shock Syndrome in a 12-Year-Old Girl Mimicking Septic Shock
by: Vindika Prasad Sinhabahu, et al.
Published: (2016-01-01)